<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953677</url>
  </required_header>
  <id_info>
    <org_study_id>DARGENT APJ 2018</org_study_id>
    <nct_id>NCT03953677</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock</brief_title>
  <acronym>Adress-Pilot</acronym>
  <official_title>A Randomized Controlled Pilot Study Evaluating the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is common in patients admitted to intensive care and hospital mortality occurs&#xD;
      in close to 50% of these patients. In half of the cases, death occurs within the first 72&#xD;
      hours in a context of multiple organ failure that does not respond to conventional therapies,&#xD;
      particularly circulatory therapies, despite increasing doses of catecholamines. Vasopressor&#xD;
      resistance in septic patients defines refractory septic shock. In one study (Conrad et al.&#xD;
      2015), the increase in blood pressure observed with an infusion of increasing doses of&#xD;
      phenylephrine (dose-response curve) made it possible to quickly and clearly identify patients&#xD;
      resistant to vasopressors at a high risk of death by refractory shock (ROC AUC 0.92). This&#xD;
      resistance is due in particular to a downregulation of α1 adrenergic receptors, linked to&#xD;
      sympathetic hyper activation associated with septic shock. To date, there is no validated&#xD;
      therapy in this situation. However, experimental data have shown that the administration of&#xD;
      α2 agonists, usually used for their sedative (dexmedetomidine) or anti-hypertensive&#xD;
      (clonidine) effect, normalizes sympathetic activity towards basal values. In animals, α2&#xD;
      agonists restore the sensitivity of alpha1 adrenergic receptors, resulting in improved&#xD;
      vasopressor sensitivity and survival. In humans, a beneficial effect on mortality was&#xD;
      suggested in the first trial testing dexmedetomidine in septic patients in 2017. This effect&#xD;
      was observed especially in the most severe patients, suggesting a restoration of sensitivity&#xD;
      to vasopressors.&#xD;
&#xD;
      The hypothesis is that the administration of dexmedetomidine in patients in refractory septic&#xD;
      shock may improve response to phenylephrine and decrease resistance to vasopressors. This&#xD;
      pilot study could lay the foundation for a randomized controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change in mean blood pressure, expressed as a percentage</measure>
    <time_frame>6 hours after the end of the initial test</time_frame>
    <description>Relative variation in mean blood pressure between the basal value at the beginning of the test and the value reached at the dose of 6 µg/kg/min (%PAM0 = PAMd/PAM0 x100)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Septic Shock</condition>
  <condition>Vasopressor Resistance</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine 100 Mcg/mL Intravenous Solution</intervention_name>
    <description>Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% glucose Infusion solution</intervention_name>
    <description>Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Septic shock, defined by the &quot;Sepsis-3&quot; criteria&#xD;
&#xD;
               -  proven or suspected infection, with modification of the SOFA score ≥ 2 points,&#xD;
&#xD;
               -  with persistent hypotension requiring vasopressors to maintain MAP ≥ 65 mmHg&#xD;
&#xD;
               -  and a serum lactate level &gt; 2 mmol/L despite adequate vascular filling&#xD;
&#xD;
          -  Adequate vascular filling: ≥ 30ml/kg, OR absence of preload-dependency criteria at&#xD;
             time of assessment (respiratory variability of the inferior vena cava, passive leg&#xD;
             lift, pulsed pressure variation)&#xD;
&#xD;
          -  Catecholamine resistance, defined by the need for a dose of norepinephrine ≥ 0,5&#xD;
             µg/kg/min for more than 2 consecutive hours within 24 hours of admission to intensive&#xD;
             care unit&#xD;
&#xD;
          -  persistence of circulatory failure with at least one of the following criteria present&#xD;
             in the 2 hours prior to randomisation: hyperlactatemia &gt; 2mmol/l, and/or mottling (≥ 1&#xD;
             score), and/or oliguria (diuresis &lt; 0,5 ml/kg/h over the last 2 hours)&#xD;
&#xD;
          -  Invasive Mechanical ventilation&#xD;
&#xD;
          -  Under sedation by midazolam or propofol&#xD;
&#xD;
          -  Informed consent obtained from a relative for patient included in an emergency&#xD;
&#xD;
          -  Patient affiliated to the national health insurance system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac arrest before inclusion and occurring before septic shock criteria are met&#xD;
&#xD;
          -  Cardiac index &lt; 2.2 l/min/m² after volume correction, or left ventricular ejection&#xD;
             fraction &lt; 40% on echocardiography&#xD;
&#xD;
          -  Bradycardia &lt; 55 bpm (apart from treatment with β-blocker) or 2nd or 3rd degree BAV&#xD;
             not equipped&#xD;
&#xD;
          -  Proven or suspected decompensation of coronary heart disease&#xD;
&#xD;
          -  Acute cerebrovascular condition within 2 weeks prior to inclusion&#xD;
&#xD;
          -  Severe hepatic insufficiency with TP and factor V &lt;50% in the absence of DIC&#xD;
             (disseminated intravascular coagulation)&#xD;
&#xD;
          -  Patient on adrenaline or vasopressors at the time of inclusion (epinephrine or&#xD;
             vasopressin stopped prior to inclusion is not a criterion for non-inclusion)&#xD;
&#xD;
          -  Patient on non-selective MAOI iproniazid within 15 days of inclusion&#xD;
&#xD;
          -  Patient for whom a decision has been made to limit the use of therapies&#xD;
&#xD;
          -  Hypersensitivity to dexmedetomidine or phenylephrine&#xD;
&#xD;
          -  Patient on dexmedetomidine before inclusion&#xD;
&#xD;
          -  Person subject to a legal protection measure (curatorship, guardianship)&#xD;
&#xD;
          -  Person subject to limited judicial protection&#xD;
&#xD;
          -  Pregnant, parturient or breastfeeding woman&#xD;
&#xD;
          -  Patient with suspected or confirmed mesenteric ischemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Auguste DARGENT</last_name>
    <phone>03.80.29.37.51</phone>
    <phone_ext>+33</phone_ext>
    <email>auguste.dargent@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Auguste DARGENT</last_name>
      <phone>03.80.29.37.51</phone>
      <phone_ext>+33</phone_ext>
      <email>auguste.dargent@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

